Janssen, J. C.
van Dijk, B.
de Joode, K.
Aarts, M. J. B.
van den Berkmortel, F. W. P. J.
Blank, C. U.
Boers-Sonderen, M. J.
van den Eertwegh, A. J. M.
de Groot, J. W. B.
Jalving, M.
de Jonge, M. J. A.
Joosse, A.
Kapiteijn, E.
Kamphuis-Huismans, A. M.
Naipal, K. A. T.
Piersma, D.
Rikhof, B.
Westgeest, H. M.
Vreugdenhil, G.
Oomen-de Hoop, E.
Mulder, E. E. A. P.
van der Veldt, Astrid A. M.
Article History
Received: 30 January 2024
Accepted: 3 May 2024
First Online: 23 May 2024
Declarations
:
: This study has been approved by the Erasmus Medical Centre Ethic committee (ref. no. MEC-2022–0571). The study will be conducted according to the principles of the Declaration of Helsinki (10th version, Fortaleza 2013) and in concordance with the Dutch Medical Research Improving Human Subjects Act and other applicable guidelines, regulations, and acts. In compliance with the International Conference on Harmonisation Good Clinical Practice (ICH-GCP) and other applicable regulations, informed consent will be obtained from all the participants to participate in the study.
: Not applicable.
: JCJ: none; BvD: none; EO: none; MBS none, BR: none; FvB: none; MA: none; AK: none; EM: none; MdJ: none; AJ: none; KN: none;AV consultancy fees (all paid to the instititute): BMS, Eisai, Ipsen, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi.DP advisory relatoptionships with Novartis, Pierre Fabre and BMS and honorarium for lecturing from Novartis. Not related to current work.EK has consultancy/advisory relationships with Bristol Myers Squibb, Novartis, Pierre Fabre, Immunocore and Lilly, and received research grants not related to this paper from Bristol Myers Squibb, Delcath, Novartis and Pierre-Fabre. Not related to current work and paid to institute.AEE has advisory relationships with Bristol-Myers Squibb, MSD Oncology, Amgen, Roche, Novartis, Sanofi, Pfizer, Ipsen, Merck, Pierre Fabre, and received research grants not related to this manuscript from Sanofi, Bristol-Myers Squibb, TEVA and Idera.MJ has consultancy/advisory relationships with Bristol Myers Squibb, Pierre Fabre, AstraZenica. Not related to current work and paid to institute.HW has consultancy/advisory relationships with Merck.KdJ has received travel expenses from Ipsen, outside the submitted work.